Details for Patent: 6,517,864

Title:	Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
Abstract:	Device for transdermal administration of tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve an effect against overactive bladder. Use of a compound having an effect against overactive bladder comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving an effect against overactive bladder. Method for achieving an effect against overactive bladder in a living body by transdermal administration of a compound comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s).
Inventor(s):	Orup Jacobsen; Lene (Gentofte, DK), Kreilgard; Bo (Hillerod, DK), Hoeck; Ulla (Hillerod, DK), Kristensen; Helle (Slangerup, DK)
Assignee:	Pharmacia AB (Stockholm, SE)
Filing Date:	Apr 30, 2001
Application Number:	09/763,654
Claims:	1. Device for transdermal administration, comprising at least one compound having a therapeutic effect against an overactive bladder in a living body which is selected from the group consisting of (R)-tolterodine or the racemate thereof, salts thereof, prodrugs thereof, and metabolites thereof, and a transdermal administration device selected from the group consisting of a reservoir, a matrix, a drug-in-adhesive, a multi-laminate, a polymer-system with no foils, a iontophoretic device, and combinations thereof, an electroporation, an electroosmosis, an electroincorporation and a jet injection device which contains said compound and which has an hourly flux rate of said at least one compound from about 0.1 .mu.g/h/cm.sup.2 to about 100 .mu.g/h/cm.sup.2. 2. Device for transdermal administration according to claim 1, characterized in that tolterodine essentially is in its R-isomeric form. 3. Device for transdermal administration according to claim 1, characterized in that tolterodine essentially is in racemic form. 4. Device for transdermal administration according to claim 1, characterized in that the (R)-tolterodine is the tolterodine metabolite (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamin e. 5. Device for transdermal administration according to claim 1 characterized in that it has a loading of tolterodine from about 0.1 mg/cm.sup.2 to about 5 mg/cm.sup.2. 6. Device for transdermal administration according to claim 1, characterized in that it has an area of from about 2 cm.sup.2 to about 100 cm.sup.2. 7. Device for transdermal administration according to claim 1, characterized in that it delivers said at least one compound for a predefined period of time. 8. Device for transdermal administration, comprising at least one compound having a therapeutic effect against an overactive bladder in a living body which is selected from the group consisting of (R)-tolterodine or the racemate thereof, salts thereof, prodrugs thereof, and metabolites thereof, wherein said at least one compound is present in a complex with cyclodextrin; and a transdermal administration device selected from the group consisting of a reservoir, a matrix, a drug-in-adhesive, a multi-laminate, a polymer-system with no foils, a iontophoretic device, and combinations thereof, an electroporation, an electroosmosis, an electroincorporation and a jet injection device which contains said compound and which has an hourly flux rate of said at least one compound from about 0.1 .mu.g/h/cm.sup.2 to about 100 .mu.g/h/cm.sup.2. 9. Device according to claim 1, characterized in that it has a release profile being, such that it, when applied on the skin at the appropriate time during day or night, administers tolterodine in such a way that a therapeutically effective systemic level of tolterodine prevails mainly during such periods of time during day and night when an effect against overactive bladder is most desirable. 10. Device according to claim 1, characterized in that it further comprises a substance enhancing transdermal penetration. 11. Device according to claim 1, characterized in that it further comprises a substance reducing irritant reactions. 12. Device according to claim 1, characterized in that it is occlusive. 13. Method for achieving an effect against an overactive bladder in a living body which comprises transdermally administering with a transdermal administration device of claim 1 at least one compound selected from the group consisting of (R)-tolterodine or the racemate thereof, salts thereof, prodrugs thereof, and metabolites thereof. 14. Method according to claim 13, characterized in that tolterodine essentially is in its R-isomeric form. 15. Method according to claim 13, characterized in that tolterodine essentially is in racemic form. 16. Method according to claim 13, characterized in that the trandsdermally administered compound comprises the (R)-tolterodine metabolite (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamin e. 17. Method according to claim 13, wherein in the treatment is achieved through systemic effect of the transdermally administered compound. 18. Method for achieving an effect against an overactive bladder and/or symptoms associated with this condition in a living body which comprises transdermally administering with a transdermal administration device of claim 1 at least one compound selected from the group consisting of (R)-tolterodine or the racemate thereof, salts thereof, prodrugs thereof, and metabolites thereof. 19. Method according to claim 13, characterized in that tolterodine is administered in such a way that a therapeutically effective systemic level of tolterodine prevails mainly during those periods of time during day and night when an effect against overactive bladder is most desirable. 20. Method according to claim 13, characterized in that tolterodine is administered in such a way that a less than therapeutically effective systemic level of tolterodine prevails mainly during those periods of time during day and night when an effect against overactive bladder is less desirable. 21. Device according to claim 1, further comprising at least one pharmaceutically acceptable carrier. 22. Device according to claim 4, further comprising tolterodine. 23. Device according to claim 1, characterized in that the device is a drug-in-adhesive or reservoir device. 24. Device according to claim 1, characterized in that the device is a combination of a drug-in-adhesive device and a reservoir device. 25. Device for transdermal administration according to claim 1, characterized in that it has an hourly flux rate of said at least one compound from about 0.2.mu.g/h/cm.sup.2 to about 35 .mu.g/h/cm.sup.2. 26. Device for transdermal administration according to claim 6, characterized in that it has an area of from about 5 cm.sup.2 to about 30 cm.sup.2. 27. Device for transdermal administration according to claim 7, characterized in that it delivers said at least one compound for 12, 24 or 48 hours. 28. Device for transdermal administration according to claim 7, characterized in that it delivers said at least one compound for up to 7 or 14 days. 29. Device according to claim 8, characterized in the cyclodextrin is .beta.-cyclodextrin. 30. Method according to claim 13, further comprising at least one pharmaceutically acceptable carrier. 31. Method according to claim 16, characterized in that the (R)-tolterodine metabolite, (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamin e, is administered together with tolterodine. 32. Method according to claim 13, wherein the transdermal administration is carried out using a drug-in-adhesive or reservoir device. 33. Method according to claim 13, wherein the transdermal administration is carried out using a combination of a drug-in-adhesive device and a reservoir device. 34. Method according to claim 18 characterized in that said at least compound is administered together with at least one pharmaceutically acceptable carrier. 35. Method according to claim 18 further comprising oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transdermal administration of a compound comprising tolterodine, salts thereof, prodrugs thereof and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s). 36. Method according to claim 5, characterized in that said oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transdermal administered compound is administered together with at least one pharmaceutically acceptable carrier.